1 Introduction Heart failure （HF） is a global health problem with an estimated prevalence of over 5.8 million in the USA and over 23 million worldwide.It represents the most common cause of hospitalization in elderl...1 Introduction Heart failure （HF） is a global health problem with an estimated prevalence of over 5.8 million in the USA and over 23 million worldwide.It represents the most common cause of hospitalization in elderly patients （〉 65 years） and its incidence has a growing trend mainly due to the aging of the population. Neurohumoral activation plays a major role in the pathophysiology. So in consequence, the cornerstone of its medical treatment is based on the inhibition of the renin-angiotensin-aldosterone system （RAAS） and the sympathetic nervous system, According to this, all patients with HF and reduced ejection fraction should be treated with an angiotensin converting enzyme inhibitor （ACEI） or an angiotensin receptor blocker （ARB） plus a beta blocker （BB） and if needed, a mineralocorticoid recep- tor antagonist （MRA）.展开更多
文摘1 Introduction Heart failure （HF） is a global health problem with an estimated prevalence of over 5.8 million in the USA and over 23 million worldwide.It represents the most common cause of hospitalization in elderly patients （〉 65 years） and its incidence has a growing trend mainly due to the aging of the population. Neurohumoral activation plays a major role in the pathophysiology. So in consequence, the cornerstone of its medical treatment is based on the inhibition of the renin-angiotensin-aldosterone system （RAAS） and the sympathetic nervous system, According to this, all patients with HF and reduced ejection fraction should be treated with an angiotensin converting enzyme inhibitor （ACEI） or an angiotensin receptor blocker （ARB） plus a beta blocker （BB） and if needed, a mineralocorticoid recep- tor antagonist （MRA）.
